TaperCommunityTaperCommunity
Forums/Drug Profiles/

Adderall Tapering Guide

amphetamine/dextroamphetamine

StimulantFDA 1996
Go to Community Forum

Boxed Warning

High potential for abuse and dependence. Misuse may cause sudden death and serious cardiovascular adverse events.

Overview

Adderall (mixed amphetamine salts) is a stimulant medication approved for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It contains a 3:1 ratio of dextroamphetamine to levoamphetamine salts.

Common Doses

IR: 5, 7.5, 10, 12.5, 15, 20, 30mg; XR: 5, 10, 15, 20, 25, 30mg

Formulations

IR tablets: 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg, 30mg; XR capsules: 5mg, 10mg, 15mg, 20mg, 25mg, 30mg

Pregnancy

Category C (risk cannot be ruled out)

Mechanism of Action

Amphetamines increase synaptic dopamine and norepinephrine via reverse transport through DAT and NET, inhibition of monoamine oxidase, and promotion of vesicular release. Effects on prefrontal cortex underlie therapeutic action in ADHD.

Taper Notes

Adderall withdrawal includes rebound fatigue, low mood, increased appetite, and cognitive slowing. A staged taper using IR fractions, XR strengths, or compound pharmacy formulations can soften the landing.

Hyperbolic Tapering Guidance

Stimulant withdrawal is typically not medically dangerous but can be subjectively severe. Slow stepwise reductions (e.g., 25% per 1-2 weeks) and matching reductions to functional demands (work, school) reduce rebound. Monitor mood — depressive symptoms can be marked in the first 2 weeks.

Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.

Tapering Protocol

Evidence-based phased reduction schedule. Always taper under medical supervision.

PhaseDurationNotes
Initial reductions1-2 weeksReduce by 25% of total daily dose. For XR users, switch to IR equivalents to enable finer reductions.
Middle reductions2-3 weeksContinue 25% reductions every 1-2 weeks. Adjust dosing schedule to match work/school demands.
Lower-dose reductions2-4 weeksBelow 10mg/day, smaller increments via tablet splitting or compounded liquid help.
Final discontinuation1-2 weeksFinal cuts to off. Plan low-demand window for rebound period.

Withdrawal Timeline

Onset

Hours after the last dose (post-dose crash) or 1-2 days after a dose reduction

📈Peak Severity

3-7 days

📉Resolution

Acute rebound resolves within 1-2 weeks

⚠️Protracted Risk

Anhedonia, low motivation, and sleep changes can persist 2-8 weeks

Community Tips

Practical insights shared by members tapering Adderall. Not medical advice — always consult your prescriber.

  • 1Plan your taper around a low-demand period — the first 2 weeks off can hit hard with fatigue, hunger, and low motivation.
  • 2Switch from XR to IR before reducing — IR gives you more granular control over the daily dose curve.
  • 3Sleep, hydration, and protein-forward eating in the rebound window are non-negotiable; appetite changes are not in your head.
  • 4If you are tapering because of cardiovascular concerns or psychosis risk, do not improvise — work with your prescriber on an appropriate pace.

Common Withdrawal Symptoms

rebound fatiguelow moodirritabilityincreased appetitedifficulty concentratingsleep disturbanceanhedonia

Interactions & Safety

Drug Interactions

  • MAOIs — contraindicated (hypertensive crisis risk)
  • Serotonergic agents (SSRIs, SNRIs, TCAs, tramadol, MDMA) — serotonin syndrome risk
  • Antihypertensives — reduced efficacy

Food Interactions

  • Acidic foods/juices reduce absorption (citrus, vitamin C)
  • Alkalinizing agents (sodium bicarbonate) increase amphetamine levels
  • Avoid combining with high-dose caffeine

Contraindications

  • Concurrent or recent (within 14 days) MAOI use
  • Advanced arteriosclerosis, symptomatic cardiovascular disease
  • Moderate-to-severe hypertension

Toxicity

Cardiovascular events (sudden death in patients with structural cardiac abnormalities), psychosis, mania, serotonin syndrome (with serotonergic agents), seizures, severe dependence, and growth suppression in children.

Pharmacokinetics

ADME Profile

Absorption

IR: Tmax ~3 hours. XR: dual-pulse release, Tmax ~7 hours. Food does not significantly affect total exposure but can delay Tmax.

Distribution

~3-4 L/kg

Metabolism

Hepatic, primarily via CYP2D6 to 4-hydroxyamphetamine and other metabolites. Some renal excretion of unchanged drug, increased by acidic urine.

Elimination

Renal (~30% unchanged at neutral urine pH; up to 70% in acidic urine).

Protein Binding

~16-20%

Clearance

Variable, urine pH-dependent

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber

Other Drug Profiles

Sources & References

Adderall (amphetamine/dextroamphetamine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.

Encyclopedic & chemical databases

Neutral, high-authority entity references.

Regulatory sources

Official prescribing information and safety notices.

Peer-reviewed research

Primary literature cited in this taper guide.

Deprescribing-specific resources

Clinician-facing references on tapering protocols.

Patient-advocacy & lived-experience

Long-running communities documenting withdrawal experience.

TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.